Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2014 Nov;19(11):1682-5. doi: 10.1016/j.drudis.2014.05.021. Epub 2014 May 29.

Trends in pharmaceutical targeting of clinical indications: 1930-2013.

Author information

  • 1Yale Center for Molecular Discovery, Yale University, 600 West Campus Drive, West Haven, CT 06516, USA. Electronic address: michael.kinch@yale.edu.
  • 2Yale Center for Molecular Discovery, Yale University, 600 West Campus Drive, West Haven, CT 06516, USA.

Abstract

An analysis of FDA-approved new molecular entities (NMEs) reveals trends in therapeutic applications. Four groupings (infectious diseases, cardiovascular diseases, autoimmune/inflammatory diseases and cancer) capture more than 60% of NMEs. Infectious diseases are the most targeted indications. Near the turn of the new millennium, the rate of new approvals for infectious diseases decreased. The absolute and relative number of NMEs targeting psychiatric, neurological and pain/itch indications also declined. By contrast, NMEs targeting cancer have risen in the past two decades as have NMEs targeting orphan indications. These results suggest the drug development community has largely been responsive to public health and market needs. However, finite resources might indicate emphasis on some unmet needs could come at the cost of others.

Copyright © 2014 Elsevier Ltd. All rights reserved.

PMID:
24881779
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk